Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV CAR-T Cells in Relapsed/Refractory EBV-positive Nasopharyngeal Carcinoma
NCT05654077Phase 1Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in nasopharyngeal carcinoma (NPC), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Dose-limiting toxicity at 28 days. Started Jan 2022; status: recruiting.
02
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05654077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654077.